Global Fexofenadine API Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Fexofenadine API Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Fexofenadine API is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itchy eyes/nose, sneezing, hives, and itching.

Market Overview:

The latest research study on the global Fexofenadine API market finds that the global Fexofenadine API market reached a value of USD 210.73 million in 2022. It’s expected that the market will achieve USD 327.09 million by 2028, exhibiting a CAGR of 7.6% during the forecast period.

Influence of Regional Conflicts on the Fexofenadine API Industry

Regional conflicts have a negative impact on the production of the API industry. The short-term adverse impact of regional conflicts on the API industry is reflected in many aspects. First, the supply balance of basic raw materials and intermediates is disrupted, thereby affecting the production of fexofenadine APIs. Second, fluctuations in the exchange rates of RMB, Japanese yen, ruble, etc. against the U.S. dollar have a certain impact on industry profits. In addition, energy prices and political factors lead to unstable transportation costs for the fexofenadine API industry. Overall, these influencing factors will put pressure on the fexofenadine API industry in the short term. For example, the continuation of the Russian-Ukrainian war will continue to push up the prices of various fuels and raw materials, which will directly increase the cost of production and sales in the industry. With the rise in global oil and natural gas prices, the production costs of bulk API companies will increase significantly.

Fexofenadine API Market Drivers Analysis

Antihistamines can be used to treat rhinitis. According to an in-depth review of allergic rhinitis by the World Allergy Organization, more than 400 million people worldwide suffer from allergic rhinitis, which remains largely underdiagnosed and untreated. In the United States, allergic rhinitis affects 10-30% of the adult population and up to 40% of children, making it the fifth most common chronic disease. Therefore, there is a large demand for Fexofenadine API in the downstream market, and the demand for therapeutic drugs for rhinitis patients promotes the development of the Fexofenadine API industry.
Urticaria is a skin disorder characterized by recurrent wheals or hives, with or without angioedema, lasting more than 6 weeks. It is an unpredictable, debilitating disease with a high disease burden and a significant negative impact on the quality of life of those affected. According to related reports, the global prevalence of urticaria in 2017 was 86 million; accounting for about 1.1% of the global population. Antihistamines can be used to treat urticaria, and the demand for treatment for urticaria patients is driving the growth of the Fexofenadine API industry

Region Overview:

From 2023-2028, Europe is estimated to witness robust growth prospects.

Company Overview:

The top three companies are Sanofi & Euroapi, Viruj Pharma, Morepenwith the revenue market share of 55.54%, 5.40% and 4.54% in 2021.

Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The company is engaged in the development, manufacture and marketing of various drugs and vaccines. Euroapi is a world leader in active pharmaceutical ingredients with approximately 200 products in Euroapi's portfolio. Euroapi's parent organization is Sanofi. Sanofi has chosen Euroapi as the name of a future leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients (APIs).

Viruj Pharma is an API manufacturer with a diversified global presence and a state-of-the-art infrastructure, built by professionals to develop and market complex, technology-driven APIs with potential therapeutic benefits.

Segmentation Overview:

Among different product types, Purity: > 98% segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the OTC segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Fexofenadine API market covered in Chapter 3:

Morepen
Farmhispania
Dr. Reddy's
JRC
Sibram
Admiron Life Sciences Private Limited
Sumitomo Chemical
Sanofi & Euroapi
Synkromax
Titan Pharma
Viruj Pharma

In Chapter 4 and Chapter 14.2, on the basis of types, the Fexofenadine API market from 2018 to 2029 is primarily split into:

Purity:<= 98%
Purity: > 98%

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Fexofenadine API market from 2018 to 2029 covers:

OTC
Prescription

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)